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Richard ChamplinAcute myeloid leukemia (AML) is primarily a dis-
ease of older people with a median age greater than
65 years. The treatment of AML in elderly patients
remains a major challenge. Older patients are more
likely to have high-risk cytogenetic abnormalities, and
age itself confers a poor prognosis. There has been little
progress with standard forms of chemotherapy [1-3].
Allogeneic stem cell transplantation (SCT) were
originally developed as a means of delivering high-dose
myeloablative chemotherapy or radiationwith the trans-
plant to provide hematologic recovery after the myeloa-
blative therapy [4]. This approach is associated with
considerable toxicity, and could only be performed in
relatively young patients in excellent general medical
condition. We have come to appreciate that much of
the benefit is derived from the graft-versus-leukemia
effect mediated by donor immune cells [5,6]. This reali-
zation has supported the development of reduced-
intensity or nonmyeloablative preparative regimens
involving lower doses of chemotherapy and/or total-
body radiation, which are sufficiently immunosuppres-
sive to prevent rejection and allow development of the
graft-versus-leukemia effect [7-10]. These reduced-
intensity regimens allow treatment of older or medically
infirm patients whowere not previously eligible for allo-geneic stem cell transplantation [11]. Reduced-intensity
regimens may be associated with a higher risk of relapse
compared with myeloablative conditioning, but
leukemia-free survival is similar in most studies [12,13].
Patients up to age75 yearshavebeen treatedwith this ap-
proach. Similar results are reportedwithmatched related
or unrelated donors [14,15].
A number of studies have shown promising results
of reduced-intensity transplants in patients with AML.
In this issue, Farag et al. [16] evaluate the results of
treatment for patients age 60 to 70 years, comparing
the results of reduced-intensity allogeneic transplanta-
tions reported to the Center for International Blood
andMarrowTransplant Research with patients receiv-
ing standard chemotherapy on Cancer and Leukemia
Group B protocols. The 2 groups had similar patients
characteristics and prognostic factors. The transplant
recipients were slightly younger than the chemother-
apy group. Patients receiving allogeneic HCT had
a significantly lower risk of relapse (32% versus 81%
at 3 years; P\ .001), and longer leukemia-free survival
(32% versus 15% at 3 years; P\ .001). Allogeneic stem
cell transplantation is a high-risk procedure, and as ex-
pected, there was a higher risk of nonrelapse mortality
at 3 years (36% versus 4%; P\ .001). Overall survival
was 37% versus 25% at 3 years (P 5 .08).
One limitation of this type of analysis is the effect of
patient selection. Older patients undergoing SCT are
selected to be in good enough medical condition to
undergo SCT and are a self-selected, highly motivated
group of patients. Allogeneic SCT involves a major
commitment on the part of the patient, requiring close
medical monitoring for at least several months. It
frequently requires patients and their caregivers to
relocate temporarily to another city to be near the trans-
plant center.Allogeneichematopoietic transplantation is
1724 Biol Blood Marrow Transplant 17:1721-1724, 2011R. Champlinnot a feasible or desirable choice for many elderly
patients.Theseconsiderationsmake it almost impossible
to conduct a prospective randomized study. However,
this and other studies demonstrate that allogeneic SCT
provides durable complete remission in a high fraction
of older patients, and the reported results consistently
compare favorably to those achieved with alternative
conventional treatments [17]. Age alone should not be
considered a contraindication to allogeneic SCT for
AML [15]. Allogeneic hematopoietic transplantation
using a reduced-intensity regimen should be considered
aneffective treatment option and anestablished standard
of care for older patients with AML.REFERENCES
1. Farag SS, Archer KJ,Mrozek K, et al. Pretreatment cytogenetics
add to other prognostic factors predicting complete remission
and long-term outcome in patients 60 years of age or older
with acute myeloid leukemia: results fromCancer and Leukemia
Group B 8461. Blood. 2006;108:63-73.
2. Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive
chemotherapy in 998patients age65 years or olderwith acutemy-
eloid leukemia or high-riskmyelodysplastic syndrome: predictive
prognostic models for outcome. Cancer. 2006;106:1090-1098.
3. Dohner H, Estey EH, Amadori S, et al. Diagnosis and manage-
ment of acute myeloid leukemia in adults: recommendations
from an international expert panel, on behalf of the European
LeukemiaNet. Blood. 2010;115:453-474.
4. Thomas ED. Bone marrow transplantation for malignant
disease. J Clin Oncol. 1983;1:517.
5. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leuke-
mia reactions after bonemarrow transplantation. Blood. 1990;75:
555-562.
6. Gale RP,Champlin RE.Howdoes bonemarrow transplantation
cure leukemia? Lancet. 1984;2:28-30.
7. ChamplinR, Khouri I, Anderlini P, et al. Nonmyeloablative pre-
parative regimens for allogeneic hematopoietic transplantation.
Bone Marrow Transplant. 2001;27:S13-S22.8. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic
hematopoietic progenitor cells with purine analog-containing
chemotherapy: harnessing graft-versus-leukemia without mye-
loablative therapy. Blood. 1997;89:4531-4536.
9. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allo-
geneic hematopoietic cell transplantation in patients with acute
myeloid leukemia. J Clin Oncol. 2010;28:2859-2867.
10. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell
transplantation using a reduced-intensity conditioning regimen-
has the capacity to produce durable remissions and long-term
disease-free survival in patients with high-risk acute myeloid
leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387-9393.
11. Estey E, de Lima M, Tibes R, et al. Prospective feasibility
analysis of reduced-intensity conditioning (RIC) regimens for
hematopoietic stem cell transplantation (HSCT) in elderly
patients with acute myeloid leukemia (AML) and high-risk
myelodysplastic syndrome (MDS). Blood. 2007;109:1395-1400.
12. Ringden O, Labopin M, Ehninger G, et al. Reduced intensity
conditioning compared with myeloablative conditioning using
unrelated donor transplants in patients with acute myeloid leu-
kemia. J Clin Oncol. 2009;27:4570-4577.
13. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs non-
myeloablative allogeneic transplantation for patients with mye-
lodysplastic syndrome or acute myelogenous leukemia with
multilineage dysplasia: a retrospective analysis. Leukemia.
2006;20:128-135.
14. Popat U, Heslop HE, Durett A, et al. Outcome of reduced-
intensity allogeneic hematopoietic stem cell transplantation
(RISCT) using antilymphocyte antibodies in patients with
high-risk acute myeloid leukemia (AML). Bone Marrow Trans-
plant. 2006;37:547-552.
15. McClune BL,Weisdorf DJ, Pedersen TL, et al. Effect of age on
outcome of reduced-intensity hematopoietic cell transplantation
for older patients with acute myeloid leukemia in first complete
remission or with myelodysplastic syndrome. J Clin Oncol. 2010;
28:1878-1887.
16. Farag SS, Maharry K, ZhangMJ, et al. Comparison of reduced-
intensity hematopoietic cell transplantation with chemotherapy
in patients age 60-70 years with acute myelogenous leukemia in
first remission. Biol Blood Marrow Transplant. 2011.
17. Gyurkocza B, Appelbaum FR. Identifying older patients with
acute myeloid leukemia who may be candidates for reduced-
intensity hematopoietic cell transplantation. J Natl Compr Canc
Netw. 2011;9:319-329. quiz 330.
